Amur Minerals Corporation Russian Sanctions Update (1783I)

TIDMAMC

RNS Number : 1783I

Amur Minerals Corporation

13 April 2022

AMUR MINERALS CORPORATION

(AIM: AMC)

Russian Sanctions Update

Amur Minerals Corporation ("Amur" or the "Company"), the nickel-copper sulphide mineral exploration and resource development company focused on the far east of Russia, announces that the Company has been continuously reviewing the EU, UK and USA sanctions documentation. Since 23 February 2022, the sanctions list additions have been frequent and rapidly evolving, changing the geopolitical landscape. To date, there has been minimal impact to the Company. As of 5 April 2022, the actions undertaken by the Company include the following:

-- Flow of funds supporting AO Kun-Manie continue and the Company has now ensured sufficient cash reserves for the subsidiary covering budgeted costs through H1 2022. Previously, AO Kun-Manie funds have been delivered to cover a 30 to 45 day period.

-- No one individual or entity identified in any transactions, contracts, or operational undertakings related to a transaction related to AO Kun-Manie are sanctioned.

-- The Company's lead legal consul representation in Moscow, Bryan Cave Leighton Paisner, is suspending operations within Russia. The Company is reviewing options for lead Russian legal representation.

 
 Company            Nomad and Broker                Public Relations 
  Amur Minerals      S.P. Angel Corporate Finance    BlytheRay 
  Corp.              LLP 
 Robin Young CEO    Richard Morrison                Megan Ray 
                     Adam Cowl                       Tim Blythe 
 +44 (0) 7981 126                                   +44 (0) 20 7138 
  818               +44 (0) 20 3470 0470             3203

For additional information on the Company, visit the Company's website, www.amurminerals.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDBKBBDABKDPQD

(END) Dow Jones Newswires

April 13, 2022 02:00 ET (06:00 GMT)

Crism Therapeutics (AQSE:AMC.GB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024